• Adocia's technology has shown promising in vivo results with the oral administration of a GLP-1 receptor agonist for the treatment of diabetes
  • First-in-Human clinical study planned for 2022 to establish proof of concept
  • The potential of this technology is being assessed across different therapeutic peptides and proteins

Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today the filing of a patent for an oral delivery technology of peptides.

Peptides and proteins are widely used as drugs, especially in the treatment of chronic diseases such as diabetes. However, almost all these drugs are only available in injectable dosage forms, which represents a burden for patients and limits the adoption of these products, especially in chronic diseases that require numerous and regular injections. In recent years, intense research efforts have focused on developing oral dosage forms. However, there are considerable technological challenges as peptides are not naturally absorbed in the digestive tract and undergo significant degradation before entering the bloodstream.

Adocia has developed a formulation which has demonstrated through preclinical studies an enhancement of the efficiency of peptide absorption by the digestive tract, making it possible to switch from injectable to oral dosage forms.

"We are pleased to add this third technology platform to our portfolio. It opens up a number of applications in markets we know well, such as diabetes and obesity," said Gérard Soula, President & CEO of Adocia. "We plan to conduct a first-in-human clinical study in 2022 to validate the proof of concept”.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic peptides and proteins for the treatment of diabetes and metabolic diseases. In the diabetes field, Adocia’s portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring six clinical-stage products and several pre-clinical products.

Adocia’s clinical pipeline includes five novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid acting insulin lispro (BioChaperone® Combo) and two combinations of a prandial insulin with amylin analog pramlintide (M1Pram and BioChaperone® LisPram). The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia.

Adocia’s preclinical pipeline includes bi-hormonal combinations for diabetes treatment: a combination of aspart rapid acting insulin analog and pramlintide (BioChaperone® AsPram), a combination of insulin glargine with GLP-1 receptor agonist (BioChaperone® Glargine Liraglutide). In addition, there are three multi-hormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone® GluExe), a combination of pramlintide and exenatide (PramExe) and a triple combination of pramlintide glucagon exenatide (BioChaperone® PramGluExe).

Adocia's portfolio is based on three technology platforms: 1) The BioChaperone® platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use; 2) A platform designed to improve cell therapy techniques using a hydrogel matrix; 3) A platform for the oral delivery of peptides.


This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the “Risk Factors” section of the universal registration document that was filed with the French Autorité des marchés financiers on April 20, 2021 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.

Adocia Gérard Soula CEO contactinvestisseurs@adocia.com Ph: +33 4 72 610 610 www.adocia.com

MC Services AG Adocia Press Relations Europe Raimund Gabriel, Shaun Brown, Andreas Jungfer adocia@mc-services.eu Ph: +49 89 210 228 0

Adocia (EU:ADOC)
Graphique Historique de l'Action
De Avr 2022 à Mai 2022 Plus de graphiques de la Bourse Adocia
Adocia (EU:ADOC)
Graphique Historique de l'Action
De Mai 2021 à Mai 2022 Plus de graphiques de la Bourse Adocia